SAGE - Sage And Axsome Face Off In Depression
On January 7, 2019, Axsome Therapeutics (AXSM) announced results from an 80-patient trial of bupropion vs AXS-05 (bupropion with dextromethorphan) in major depressive disorder ((MDD)). I recently wrote about results from the trial and the five additional upcoming catalysts for AXSM. Comparisons were soon drawn between AXS-05 and SAGE-217, a drug under development by SAGE Therapeutics (SAGE) which produced impressive results in an 89-patient MDD trial in late 2017. The two drugs could be set to compete in the future in MDD and so this article will make an attempt at